Muramatsu, M. et al. Class switching recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102553-563 (2000).
Viant, C. et al. Antibody affinity shapes fate choice between memory and germinal center B cells. Cell 1831298–1311.e11 (2020).
Forthal, D. N. Functions of Antibodies. Microbiol. Spectr. 21–17 (2014).
Google scholar
Singh, S. et al. Monoclonal Antibodies: A Review. Curr. Clin. Pharmacol. 1385-99 (2018).
Google scholar
Mullard, A. FDA Approves 100th Monoclonal Antibody Product. Wet. Rev. Drug Explorer. 20491-495 (2021).
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibodies of predetermined specificity. Nature 256495-497 (1975).
Clackson, T., Hoogenboom, HR, Griffiths, AD & Winter, G. Making antibody fragments using phage display libraries. Nature 352624-628 (1991).
Pedrioli, A. & Oxenius, A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 421143-1158 (2021).
Mayes, PA, Hance, KW & Hoos, A. The promise and challenges of immune agonist development in cancer. Wet. Rev. Drug Explorer. 17509-527 (2018).
White, AL et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 1871754-1763 (2011).
Yu, X. et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer cell 33664–675.e4 (2018).
White, AL et al. Conformation of the human immunoglobulin G2 hinge confers superagonist properties on anticancer immunostimulatory antibodies. Cancer cell 27138-148 (2015).
Ahonen, C. et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Wet. Immunol. 3451-456 (2002).
Dahan, R. et al. Therapeutic activity of agonistic, human monoclonal anti-CD40 antibodies requires selective FcγR involvement. Cancer cell 29820-831 (2016).
Yu, X. et al. Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity. Cancer cell 37850–866.e7 (2020).
Ma, DY & Clark, EA The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21265-272 (2009).
Yu, X. et al. TNF receptor agonists induce different receptor clusters to mediate differential agonist activity. common. Biol. 4772 (2021).
Chester, C., Sanmamed, MF, Wang, J. & Melero, I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical outcomes, and future strategies. Blood 13149-57 (2018).
Chin, SM et al. Structure of the 4-1BB/4-1BBL complex and different binding and functional properties of utomilumab and urelumab. Wet. Common. 94679 (2018).
Google scholar
Gong, J., Chehrazi-Raffle, A., Reddi, S. & Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registry trials and future considerations. J. Immunother. Cancer 68 (2018).
Google scholar
Paluch, C., Santos, AM, Anzilotti, C., Cornall, RJ & Davis, SJ Immune checkpoints as therapeutic targets in autoimmunity. Front side. Immunol. 92306 (2018).
Google scholar
Curnock, AP et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. JCI insight 6e152468 (2021).
Google scholar
Bryan, CM et al. Computational design of a synthetic PD-1 agonist. Proc. Natl Acad. Know United States of America 118e2102164118 (2021).
Lee, JY et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Wet. Common. 713354 (2016).
Bardhan, K. et al. Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Science. representative 917252 (2019).
Google scholar
Chemnitz, JM, Parry, RV, Nichols, KE, June, CH & Riley, JL SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switching motif of programmed death 1 in primary human T cell stimulation, but only receptor ligation prevents activation of T cells. J. Immunol. 173945-954 (2004).
Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, VA Revisiting the PD-1 pathway. Science. Adv. 6eabd2712 (2020).
Jones, B., Tite, JP & Janeway, CA Jr. Several phenotypic variants of the mouse B-cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, IA-restricted T-cell clones. J. Immunol. 136348-356 (1986).
Lu, RM et al. Development of therapeutic antibodies for the treatment of disease. J. Biomed. Science. 271 (2020).
Tabasinezhad, M. et al. Trends in therapeutic antibody affinity maturation: from in vitro to next-generation sequencing approaches. Immunol. Lit. 212106–113 (2019).
Chodorge, M. et al. A series of antibodies against the Fas receptor agonist showing an inverse correlation between affinity and potency. Cell death differs. 191187-1195 (2012).
Segal, NH et al. Phase I study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin. cancer res. 241816-1823 (2018).
Rudnick, SI et al. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. cancer res. 712250-2259 (2011).
Wajant, H. Principles of antibody-mediated TNF receptor activation. Cell death differs. 221727-1741 (2015).
Roghanian, A. et al. Antagonistic human FcγRIIB (CD32B) antibodies have antitumor activity and overcome resistance to antibody therapy in vivo. Cancer cell 27473-488 (2015).
Krissinel, E. Stock-based detection of oligomeric protein states in jsPISA. Nucleic Acids Res. 43W314-W319 (2015).
Krissinel, E. & Henrick, K. Derivation of macromolecular assemblies from crystalline state. J Mol. Biol. 372774-797 (2007).
Davis, CB et al. Combining a PD-1 antagonist and a 4-1BB agonist for cancer treatment. International Patent Publication Number WO 2015/119923 A1 (2015).
Korman, AJ et al. Human monoclonal antibodies against programmed death 1 (PD-1) and methods of treating cancer with anti-PD01 antibodies alone or in combination with other immunotherapeutics. International Patent Publication Number WO 2006/121168 A1 (2006).
Keler, T et al. Antibodies binding human CD27 and uses thereof. U.S. Patent 9,169,325 (2015).
Hanke, T et al. Nucleic acids encoding anti-CD28 superagonistic antibodies. U.S. Patent 7,585,960 (2009).
Arakawa, F. et al. Cloning and sequencing of the VH and VK genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J. Biochem. 120657-662 (1996).
Meyer, L. et al. A simplified workflow for sequencing monoclonal antibodies. PLOS ONE 14e0218717 (2019).
Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha. J. Exp. Med. 1791109-1118 (1994).
Poort, D. et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577399-404 (2020).
Fernandes, RA et al. Immune receptor inhibition by forced recruitment of phosphatase. Nature 586779-784 (2020).
Austin, CD et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapies trastuzumab and geldanamycin. mole. Biol. Cell 155268-5282 (2004).
Sopp, JM et al. On-target IgG hexamerization driven by a tailpiece C-terminal IgM fusion variant mediates enhanced complement activation. common. Biol. 41031 (2021).